Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

    Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.

    Diabetes Care. 2009 Jun;32(6):1037-42. Epub 2009 Feb 24.PMID: 19244091 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.

    Morrato EH, Newcomer JW, Allen RR, Valuck RJ.

    J Clin Psychiatry. 2008 Feb;69(2):316-22.PMID: 18251625 [PubMed - indexed for MEDLINE]Related articles

    3.

    Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

    Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J.

    J Clin Psychopharmacol. 2009 Feb;29(1):26-32.PMID: 19142103 [PubMed - indexed for MEDLINE]Related articles

    4.

    Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

    Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW.

    Am J Psychiatry. 2009 Mar;166(3):345-53. Epub 2009 Jan 15.PMID: 19147694 [PubMed - indexed for MEDLINE]Related articles

    5.

    Diabetes and lipid screening among patients in primary care: a cohort study.

    Rifas-Shiman SL, Forman JP, Lane K, Caspard H, Gillman MW.

    BMC Health Serv Res. 2008 Jan 30;8:25.PMID: 18234107 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

    Newcomer JW.

    CNS Drugs. 2005;19 Suppl 1:1-93. Review.PMID: 15998156 [PubMed - indexed for MEDLINE]Related articles

    7.

    Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.

    Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F.

    J Am Pharm Assoc (2003). 2008 May-Jun;48(3):393-400.PMID: 18595825 [PubMed - indexed for MEDLINE]Related articles

    8.

    Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.

    Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF.

    Neuroendocrinology. 2007;85(4):249-56. Epub 2007 Jun 15.PMID: 17570902 [PubMed - indexed for MEDLINE]Related articles

    9.

    Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.

    Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, Ujkaj M, Pastorelli F, Berardi D.

    BMC Psychiatry. 2006 Mar 16;6:11.PMID: 16542430 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. The Epidemiology of Diabetes Complications Study.

    Williams KV, Erbey JR, Becker D, Orchard TJ.

    Diabetes Care. 1999 Jul;22(7):1084-91.PMID: 10388972 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.

    Erdman DM, Cook CB, Greenlund KJ, Giles WH, El-Kebbi I, Ryan GJ, Gallina DL, Ziemer DC, Dunbar VG, Phillips LS.

    Diabetes Care. 2002 Jan;25(1):9-15.PMID: 11772894 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [Schizophrenia, diabetes mellitus and antipsychotics]

    Gury C.

    Encephale. 2004 Jul-Aug;30(4):382-91. Review. French. PMID: 15538314 [PubMed - indexed for MEDLINE]Related articles

    13.

    LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.

    Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C.

    J Manag Care Pharm. 2007 Oct;13(8):652-63.PMID: 17970603 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation]

    Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

    G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian. PMID: 18773746 [PubMed - indexed for MEDLINE]Related articles

    15.

    Naturalistic impact of second-generation antipsychotics on weight gain.

    Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, Oderda GM.

    Ann Pharmacother. 2006 Apr;40(4):626-32. Epub 2006 Mar 28.PMID: 16569802 [PubMed - indexed for MEDLINE]Related articles

    18.

    No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.

    Rondanelli M, Sarra S, Antoniello N, Mansi V, Govoni S, Falvo F, Solerte SB, Ferrari E.

    Minerva Med. 2006 Apr;97(2):147-51.PMID: 16760853 [PubMed - indexed for MEDLINE]Related articles

    19.

    Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria.

    Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ.

    Lancet. 1999 Aug 21;354(9179):622-5.PMID: 10466662 [PubMed - indexed for MEDLINE]Related articles

    20.

    Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.

    Østbye T, Curtis LH, Masselink LE, Hutchison S, Wright A, Dans PE, Schulman KA, Krishnan RR.

    Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):407-15.PMID: 15372671 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data